14 results
To study whether ticagrelor, added to acetylsalicylic acid, modulates the inflammatory response to the administration of lipopolysaccharide (LPS) in humans in vivo.
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
The present study will investigate whether implementation of the Hemostasis Management System (HMS) in cardiothoracic surgery will result in higher doses of heparin and lower doses of protamine, thereby leading to a less impaired postoperative…
To evaluate safety of 3-months versus standard 12-months of DAPT
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
To assess the efficacy, safety and cost-effectiveness of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel or prasugrel/ticagrelor.
To investigate if antiplatelet therapy consisting of ticagrelor plus ASA is superior to clopidogrel plus ASA in preventing ischaemic brain lesions occurring as a result of CAS assessed on magnetic resonance imaging (MRI).
Our main goal is to establish whether there is difference in the effect between the use of aspirin, dualtherapy aspirin/clopidogrel, or ticagrelor on the occurrence of atherothrombotic events in patients following lower extremity peripheral…
The aim of this study is to evaluate the feasibility and safety of CYP2C19-genotype-guided p2y12 inhibitor selection in patients who are indicated for (D)OAC and require PCI. Both safety and efficacy outcomes will be captured. Also a cost-benefit…
The aim of this study is to assess the pharmacodynamic effects of different P2Y12 inhibiting therapy (clopdiogrel vs ticagrelor) in patients at high risk for HPR identified according to the ABCD-GENE score in PCI treated patients also requiring OAC…
The new drug delivery device is a rod-shaped metal bar, called an ocular coil. The coil can be loaded with one (or more) drug(s) en can be placed easily in the lower eyelid of the eye. In this way, the drug can be released to the eye in a constant…
To assess the safety, efficacy and net clinical benefit of clopidogrel versus the new antiplatelet drugs i.e. ticagrelor and prasugrel in patients older than 70 years.
To evaluate if an individualized antithrombotic P2Y12-inhibitor monotherapy in comparison to an individualized DAPT treatment is superior regarding bleeding events and non-inferior regarding ischemic events in patient with CCS after PCI.
The primary objective of this study is to assess the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after PCI with a new generation drug-eluting in non-ST-elevation acute coronary syndrome…